All In Biotech

Drug Trial Radar · NCT05103241

A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers

Single-center, Open-label, Non-randomized and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 40 mg/100 μCi [14C]GP681 in Healthy Chinese Male Volunteers

Last checked: Nov 19, 2026Latest source record: Dec 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Oct 26, 2021

Primary completion

Nov 22, 2021

Study completion Nov 22, 2021

Sponsor

Sponsor type
Industry
First posted
Nov 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]GP681 in healthy Chinese male volunteers, revealing the overall pharmacokinetic characteristics of GP681 in humans, and providing a reference for the rational administration.

Conditions

  • Healthy Volunteers

Interventions

  • [14C] GP681Drug

    40 mg suspension containing 100μCi of \[14C\]GP681

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The distribution of GP681 in the whole blood and plasma, and the radioactive pharmacokinetics following the single orally administered [14C]GP681 in healthy Chinese male volunteers.Time frame: Up to 336 hours (approx) from the start of administration.
  2. Quantitive analysis of whole radioactivity of excrement of orally administered [14C]GP681 in healthy Chinese male subjects to obtain the mass balance data and the main excretion pathway in human body.Time frame: Up to 432 hours (approx) from the start of administration.
  3. Quantitive analysis of the concentrations of GP681 and its major metabolites (such as GP1707D07) in plasma using the validated LC-MS/MS to obtain pharmacokinetic data.Time frame: Up to 336 hours (approx) from the start of administration.
  4. Identification of the main metabolites and biotransformation pathway of GP681 following the single orally administered [14C]GP681 in healthy Chinese male volunteersTime frame: Up to 432 hours (approx) from the start of administration.
  5. Evaluation of safety following the single orally administered [14C]GP681 in healthy Chinese male volunteers.Time frame: Up to 432 hours (approx) from the start of administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.